Brooklyn ImmunoTherapeutics appoints interim CEO Matt Angel, CFO Andrew Jackson; CEO Federoff resigns
Ernexa Therapeutics Inc.
CEO Howard Federoff resigned effective May 26, 2022; received $225K bonus, $450K salary continuation, and accelerated stock options covering 1,420,095 shares.
Matt Angel, co-founder of Factor Bioscience, appointed interim President and CEO; Factor was a Novellus acquisition counterparty that received $1.7M cash and ~2.58M shares.
Andrew Jackson named CFO; receives $415K base salary, 40% target bonus, and a stock option grant for 664,800 shares.
Four directors (Heather Redman, Erich Mohr, Erin Enright, Dennis Langer) will not stand for reelection at postponed annual meeting.
2022 annual meeting postponed to a later date; new proxy statement expected.
On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
On May 9 , 2022, the Board appointed Andrew Jackson as the Chief Finan
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Matthew Angel was appointed as interim President and Chief Executive Officer at Ernexa Therapeutics Inc..
Action
appointed
Role
interim President and Chief Executive Officer
Exact text from the filing
On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
Howard J. Federoff, M.D., Ph.D. resigned as Chief Executive Officer at Ernexa Therapeutics Inc..
Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.